Khalid Matin is an Oncology physician affiliated with Virginia Commonwealth University. OpenAlex indexes 51 publications with 868 citations (h-index 14); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1250 E Marshall St
Dept. Of Internal Medicine-Hematology/oncology
Richmond, VA 232985051
Telephone
804-828-7999Registry record last updated 14 Aug 2013.
Clinical trials
- Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer
Sponsor: Virginia Commonwealth University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year20252 payments
- GlaxoSmithKline, LLC.Program year20252 payments
- Intera Oncology, IncProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
40%Serotonin-3 Receptor Antagonist19.2%Ondansetron Hcl100%Part D≥34 patientsAntidiarrheal microorganisms12.4%Creon100%Part D<11 patients+ 1 more class in this area
Nervous system
32.4%Phenothiazine21.6%Prochlorperazine Maleate100%Part D≥36 patientsOpioid Agonist6.4%Oxycodone Hcl100%Part D≥14 patients+ 1 more class in this area
Cancer & immunology
12%Kinase inhibitor12%Sunitinib Malate60%Everolimus40%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2019–2025 per NIH RePORTER. The latest:
- VCU Massey Comprehensive Cancer Center NCI Community Oncology Research Program
Virginia Commonwealth University
FY2025$1,239,982UG1CA189869 - VCU Massey Cancer Center Minority/Underserved NCI Community Oncology Research Program
Virginia Commonwealth University
FY2024$1,189,949UG1CA189869 - VCU Massey Cancer Center Minority/Underserved NCI Community Oncology Research Program
Virginia Commonwealth University
FY2023$1,075,978UG1CA189869
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer
New England Journal of Medicine
2026
Similar KOLs
Other experts from the same institution or the same specialty.
Jasmohan Bajaj, MD
Virginia Commonwealth University
Velimir Luketic, MD
Virginia Commonwealth University
Patrick Ching, MD, MPH
Virginia Commonwealth University
Robert Delorenzo, MD
Virginia Commonwealth University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”